NeuroMetrix, Inc. (NASDAQ:NURO) received a $16.00 target price from research analysts at HC Wainwright in a research note issued on Thursday, June 15th. The firm presently has a “buy” rating on the medical device company’s stock.

A number of other research analysts also recently weighed in on NURO. Zacks Investment Research downgraded NeuroMetrix from a “buy” rating to a “hold” rating in a research note on Thursday, March 30th. ValuEngine downgraded NeuroMetrix from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd.

NeuroMetrix (NASDAQ:NURO) opened at 2.6393 on Thursday. NeuroMetrix has a 1-year low of $2.56 and a 1-year high of $14.32. The stock’s 50 day moving average is $3.28 and its 200-day moving average is $1.33. The firm’s market cap is $3.35 million.

NeuroMetrix (NASDAQ:NURO) last announced its quarterly earnings results on Thursday, April 20th. The medical device company reported ($7.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($3.92) by $3.36. NeuroMetrix had a negative net margin of 99.95% and a negative return on equity of 175.24%. The firm had revenue of $4.31 million for the quarter, compared to analyst estimates of $4.17 million. Analysts forecast that NeuroMetrix will post ($10.50) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “NeuroMetrix, Inc. (NURO) Given a $16.00 Price Target at HC Wainwright” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at

An institutional investor recently raised its position in NeuroMetrix stock. Sabby Management LLC increased its position in shares of NeuroMetrix, Inc. (NASDAQ:NURO) by 81.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 302,104 shares of the medical device company’s stock after buying an additional 135,836 shares during the period. Sabby Management LLC owned 2.98% of NeuroMetrix worth $187,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 64.07% of the company’s stock.

NeuroMetrix Company Profile

NeuroMetrix, Inc is a healthcare company combining bioelectrical and digital medicine to address chronic health conditions, including chronic pain, sleep disorders and diabetes. The Company is engaged in the sale of medical equipment, and consumables and accessories. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests.

Receive News & Stock Ratings for NeuroMetrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix Inc. and related stocks with our FREE daily email newsletter.